Publicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (12)

2023

  1. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

  2. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2022

  1. Generation of NKX2.5GFP Reporter Human iPSCs and Differentiation Into Functional Cardiac Fibroblasts

    Frontiers in Cell and Developmental Biology, Vol. 9

  2. Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome

    Frontiers in Immunology, Vol. 13

  3. Risk Factors of DAIR Failure and Validation of the KLIC Score: A Multicenter Study of Four Hundred Fifty-Five Patients

    Surgical Infections, Vol. 23, Núm. 3, pp. 280-287

2021

  1. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

  2. The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial

    Cancers, Vol. 13, Núm. 10

2020

  1. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

    EClinicalMedicine, Vol. 25

  2. Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

    Frontiers in Immunology

  3. Spanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational research

    Cytotherapy, Vol. 22, Núm. 1, pp. 1-5

2019

  1. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

    Frontiers in Immunology, Vol. 10, Núm. JUN

2012

  1. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma

    British Journal of Haematology, Vol. 158, Núm. 6, pp. 712-726